Evidence map›Paper›PMID 36846655›Full record

ArticleHeliyon2023

Thrombospondin-1 induction and VEGF reduction by proteasome inhibition.

Fawzia Bardag-Gorce, Carter Hoffman, Imara Meepe, Monica Ferrini, Richard H Hoft, Joan Oliva, Yutaka Niihara

Abstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. The Role of the Ubiquitin System in Eye Diseases.Life (Basel, Switzerland) · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fawzia Bardag-GorceThe Lundquist Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA.
Carter HoffmanThe Lundquist Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA.
Imara MeepeThe Lundquist Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA.
Monica FerriniCharles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
Richard H HoftThe Lundquist Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA.
Joan OlivaEmmaus Medical, 21250 Hawthorne Blvd, Suite 800, Torrance, CA, 90505, USA.
Yutaka NiiharaThe Lundquist Institute at Harbor UCLA Medical Center, Torrance, CA, 90502, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study focuses on investigating the expression of thrombospondin-1 (TSP-1), a natural inhibitor of neovascularization. Immunofluorescent staining was used to detect the expression of TSP-1 in rabbit corneal tissue with vascularization induced by limbectomy. TSP-1 was detected in healthy and Cultured Autologous Oral Mucosal Epithelial Cell Sheet (CAOMECS) grafted rabbit corneas. TSP-1 was not detected in diseased corneas. Rabbit and human primary oral mucosal and corneal epithelial cells were cultured and treated with proteasome inhibitor (PI) in vitro. Changes in the expression of TSP-1, HIF-1 alpha and 2 alpha, VEGF-A, and VEGF receptor were analyzed by Western blotting. Neovascularization developed in rabbits' corneas as early as 1 month after limbectomy and was stable for at least 3 months. HIF-1 alpha and VEGF-A expression was reduced in CAOMECS grafted corneas, as compared to sham corneas. While TSP-1 expression was decreased in injured corneas, it was expressed in CAOMECS grafted corneas, but still less expressed compared to healthy corneas. PI treatment, of human oral mucosal and corneal epithelial cells increased TSP-1 expression and reduced VEGF-A expression. The results showed that TSP-1 expression was lost in injured corneal surface and that CAOMECS grafting restored TSP-1 expression to certain extent. Proteasome inhibition treatment increased TSP-1 and decreased VEGF-A expression in human oral mucosal and corneal epithelial cells. The result suggests that corneal neovascularization could be managed with the inhibition of the proteasome after CAOMECS grafting and increase corneal transparency.

Indexed as

Corneal vascularizationProteasome inhibitionThrombospondin-1VEGF

Identifiers

PMID36846655
PMCPMC9950833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.